🇺🇸 FDA
Patent

US 8828977

Method of treating a subject suffering from degenerative disc disease using a matrix metalloprotease inhibitor

granted A61KA61K31/155A61K31/198

Quick answer

US patent 8828977 (Method of treating a subject suffering from degenerative disc disease using a matrix metalloprotease inhibitor) held by Discogen, LLC expires Mon Sep 04 2034 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Discogen, LLC
Grant date
Tue Sep 09 2014 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Sep 04 2034 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
9
CPC classes
A61K, A61K31/155, A61K31/198, A61K38/4886, A61P